[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364472-105":59,"doc-detail-364472-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","expression-patterns-of-dll3-across-neuroendocrine-and-non-neuroendocrine-neoplasms-reveal-broad-opportunities-for-therapeutic-targeting","Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting","","Neuroendocrine neoplasms (NEN) encompass diverse malignancies with limited precision therapy options. DLL3-targeted therapies have shown clinical activity in aggressive NENs, prompting a comprehensive characterization of DLL3 expression. Paired DNA/RNA sequencing across 1,589 NENs and pan-cancer assessment of 203,252 tumors across 47 cancer types identify clinical and molecular correlates. High DLL3 transcript levels associate with aggressive histology and mutational patterns and worse survival in NENs from lung, pancreas, stomach, and small bowel. Site of origin explains much of DLL3 heterogeneity, while non-neuroendocrine cancers show DLL3 enrichment in gliomas, Merkel cell carcinomas, medulloblastomas, and melanomas with survival-linked differences.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/expression-patterns-of-dll3-across-neuroendocrine-and-non-neuroendocrine-neoplasms-reveal-broad-opportunities-for-therapeutic-targeting/364472/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/expression-patterns-of-dll3-across-neuroendocrine-and-non-neuroendocrine-neoplasms-reveal-broad-opportunities-for-therapeutic-targeting/364472.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of characterizing DLL3 in this study?","Question",{"text":112,"@type":113},"To characterize DLL3 expression and identify its clinical and molecular correlates across neuroendocrine and non-neuroendocrine cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the study assess DLL3 expression across cancers?",{"text":117,"@type":113},"It interrogated paired DNA and RNA sequencing from 1,589 NENs and analyzed 203,252 tumors across 47 cancer types.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinical associations were observed for high DLL3 levels?",{"text":121,"@type":113},"High DLL3 transcript levels correlated with more aggressive histologic and mutational patterns in NENs and reflected adverse survival outcomes in NENs from lung, pancreas, stomach, and small bowel.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364472,1790167403,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-24-0501](https://doi.org/10.1158/2767-9764.CRC-24-0501)  OPEN ACCESS  \nExpression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting  \nJohn R. Lozada1,2,3, Andrew Elliott4, Mark G. Evans4, James Wacker4, Kathleen M. Storey1, Emily A. Egusa3, Nicholas A. Zorko1,2, Akhilesh Kumar1, Anthony Crymes5, Elisabeth I. Heath6, Benedito A. Carneiro7, Heloisa P. Soares8, Frank Cichocki1,2, Jeffrey S. Miller1,2, Emil Lou1,2, Himisha Beltran9,  \nEmmanuel S. Antonarakis1,2, Charles J. Ryan2, and Justin H. Hwang1,2  \n􀀶  \nABSTRACT  \nNeuroendocrine neoplasms (NEN) encompass a diverse set of malignancies with limited precision therapy options. Recently, therapies targeting DLL3 have shown clinical efficacy in aggressive NENs, including small cell lung cancers and neuroendocrine prostate cancers. Given the continued development and expansion of DLL3-targeted therapies, we sought to characterize the expression of DLL3 and identify its clinical and molecular correlates across diverse neuroendocrine and non-neuroendocrine cancers. Here, we interrogated paired DNA and RNA-sequencing from 1,589 NENs across 29 sites, as well as 203,252 tumors across 47 cancer types. We found that high transcriptomic levels of DLL3 correlated with more aggressive histologic and mutational patterns in NENs, with adverse survival outcomes being reflected in NENs originating from the lung, pancreas, stomach, and small bowel. The heterogeneity in DLL3 expression across NENs was largely explained by site of origin, with lung, prostate, and bladder NENs exhibiting relatively high levels of DLL3, whereas gastroenteropancreatic NENs displayed relatively low expression levels. Although the therapeutic targeting of DLL3 may be less applicable for  \ngastroenteropancreatic NENs, we did find an upregulation of alternative targets such as SEZ6, CELSR3, and SSTR2 in these settings. Lastly, expanding our investigation into non-neuroendocrine cancers, we detected an enrichment of DLL3 in both low-grade and high-grade gliomas, Merkel cell carcinomas, medulloblastomas, and melanomas, with such enrichment being associated with prolonged overall survival in gliomas, but worse overall survival in melanomas. Altogether, we demonstrate that DLL3 represents an attractive target for subsets of neuroendocrine and non-neuroendocrine cancers and uncover opportunities for future therapeutic strategies.  \nSignificance: DLL3-targeted therapies have recently shown robust clinical efficacy in aggressive neuroendocrine cancers, positioning them to fulfill a great unmet need in these settings. Here, we examine the clinical and biological correlates of DLL3 expression in both neuroendocrine and non-neuroendocrine cancers. Our findings may stimulate the development and application of DLL3-targeted therapies, as well as other precision therapies, in neuroendocrine cancers and beyond.  \n1Division of Hematology, Oncology, and Transplantation, University of Minnesota-Twin Cities, Minneapolis, Minnesota. 2Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, Minnesota. 3Medical Scientist Training Program (MD/PhD), University of Minnesota, Minneapolis, Minnesota. 4Caris Life Sciences, Phoenix, Arizona. 5Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California. 6Department of Oncology, Wayne State University Karmanos Cancer Institute, Detroit, Michigan. 7Legorreta Cancer Center, Brown University, Providence, Rhode Island. 8Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. 9Dana-Farber Cancer Institute, Boston, Massachusetts.  \nC.J. Ryan and J. H. Hwang are co-senior authors of this article.  \nCorresponding Authors: Charles J. Ryan, Masonic Cancer Center, University of Minnesota-Twin Cities, Mayo Mail Code 806, 420 Delaware Street South East, Minneapolis, MN 55455. E-mail: [ryanc@umn.edu](ryan","cbCaibEdCvILbn1f","https://ap.wps.com/l/cbCaibEdCvILbn1f","pdf",2810242,"English","# Abstract\n# Significance\n# Introduction\n# Pan-Cancer Correlates of DLL3 Expression","[{\"question\":\"What was the main goal of characterizing DLL3 in this study?\",\"answer\":\"To characterize DLL3 expression and identify its clinical and molecular correlates across neuroendocrine and non-neuroendocrine cancers.\"},{\"question\":\"How did the study assess DLL3 expression across cancers?\",\"answer\":\"It interrogated paired DNA and RNA sequencing from 1,589 NENs and analyzed 203,252 tumors across 47 cancer types.\"},{\"question\":\"What clinical associations were observed for high DLL3 levels?\",\"answer\":\"High DLL3 transcript levels correlated with more aggressive histologic and mutational patterns in NENs and reflected adverse survival outcomes in NENs from lung, pancreas, stomach, and small bowel.\"}]","Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting | PDF",1790157703,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f9d5baefbc11bd9af57d2aaff0d5663.webp",983,1263,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e6fee68a0e83b8467349f0276731c6b.webp",982,1262,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28cd373624beeca8073f325ebdee1e03.webp",981,1261,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e529c5fa4e866f4a6667447a8189241d.webp",980,1259]